Literature DB >> 2180496

Beta-lactam antibiotic-induced platelet dysfunction: evidence for irreversible inhibition of platelet activation in vitro and in vivo after prolonged exposure to penicillin.

S F Burroughs1, G J Johnson.   

Abstract

beta-Lactam antibiotics cause platelet dysfunction with bleeding complications. Previous in vitro studies documented reversible inhibition of agonist-receptor interaction. This mechanism is inadequate to explain the effect of beta-lactam antibiotics in vivo. Platelet function does not return to normal immediately after drug treatment, implying irreversible inhibition of platelet function. We report here evidence of irreversible platelet functional and biochemical abnormalities after in vitro and in vivo exposure to beta-lactam antibiotics. Irreversible binding of [14C]-penicillin (Pen) occurred in vitro. After 24 hours' in vitro incubation with 10 to 20 mmol/L Pen, or ex vivo after antibiotic treatment, irreversible functional impairment occurred; but no irreversible inhibition of alpha 2 adrenergic receptors, measured with [3H]-yohimbine, or high-affinity thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors, measured with agonist [3H]-U46619 and antagonist [3H]-SQ29548, occurred. However, low-affinity platelet TXA2/PGH2 receptors were decreased 40% after Pen exposure in vitro or in vivo, indicating irreversible membrane alteration. Two postreceptor biochemical events were irreversibly inhibited in platelets incubated with Pen for 24 hours in vitro or ex vivo after antibiotic treatment. Thromboxane synthesis was inhibited 28.3% to 81.7%. Agonist-induced rises in cytosolic calcium ([Ca2+]i) were inhibited 40.1% to 67.5% in vitro and 26.6% to 52.2% ex vivo. Therefore, Pen binds to platelets after prolonged exposure, resulting in irreversible dysfunction attributable to inhibition of TXA2 synthesis and impairment of the rise in [Ca2+]i. The loss of low-affinity TXA2/PGH2 receptors suggests that the primary site of action of these drugs is on the platelet membrane.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180496

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Platelet dysfunction and inhibition of multiple electrode platelet aggregometry caused by penicillin.

Authors:  Christian Schulz; Olga von Beckerath; Rainer Okrojek; Nicolas von Beckerath; Steffen Massberg
Journal:  Thromb J       Date:  2010-07-21

2.  Bovine platelets retain functional activity in the presence of penicillin G.

Authors:  P A Gentry; P D Mansell; D J Mason; P D Conlon
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

3.  Intracranial haemorrhage in thrombocytopenic haematology patients--a nested case-control study: the InCiTe study protocol.

Authors:  Lise J Estcourt; Simon J Stanworth; Dave Collett; Mike F Murphy
Journal:  BMJ Open       Date:  2014-02-07       Impact factor: 2.692

Review 4.  The Underestimated Role of Platelets in Severe Infection a Narrative Review.

Authors:  Alberto Fogagnolo; Gianluca Calogero Campo; Matilde Mari; Graziella Pompei; Rita Pavasini; Carlo Alberto Volta; Savino Spadaro
Journal:  Cells       Date:  2022-01-26       Impact factor: 6.600

5.  Primary hemostasis in fetal growth restricted neonates studied via PFA-100 in cord blood samples.

Authors:  Maria Kollia; Nicoletta Iacovidou; Zoi Iliodromiti; Abraham Pouliakis; Rozeta Sokou; Vasiliki Mougiou; Maria Boutsikou; Marianna Politou; Theodora Boutsikou; Serena Valsami
Journal:  Front Pediatr       Date:  2022-09-08       Impact factor: 3.569

6.  Different degrees of NADPH oxidase 2 regulation and in vivo platelet activation: lesson from chronic granulomatous disease.

Authors:  Roberto Carnevale; Lorenzo Loffredo; Valerio Sanguigni; Alessandro Plebani; Paolo Rossi; Claudio Pignata; Baldassarre Martire; Andrea Finocchi; Maria Cristina Pietrogrande; Chiara Azzari; Anna Rosa Soresina; Silvana Martino; Emilia Cirillo; Francesco Martino; Pasquale Pignatelli; Francesco Violi
Journal:  J Am Heart Assoc       Date:  2014-06-27       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.